Development of Oral Azacitidine With Cedazuridine for Myelodysplastic Syndrome (MDS) and Myeloproliferative Neoplasms (MPN) Including Chronic Myelomonocytic Leukemia (CMML) by Targeting Pharmacokinetic AUC Equivalence vs Subcutaneous Azacitidine

被引：0

作者：

Garcia-Manero, Guillermo ^{[1
]}

McCloskey, James ^{[2
]}

Scott, Bart L. ^{[3
]}

Griffiths, Elizabeth A. ^{[4
]}

Kiner-Strachan, Bonnie ^{[5
]}

Roboz, Gail J. ^{[6
,7
]}

Meyer, Janelle ^{[8
]}

Chan, Winny ^{[9
]}

Sano, Yuri ^{[9
]}

Oganesian, Aram ^{[9
]}

Keer, Harold K. ^{[9
]}

Savona, Michael R. ^{[10
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[2] Hackensack Med Ctr, John Thuerer Canc Ctr, Hackensack, NJ USA

[3] Fred Hutchinson Canc Ctr, Seattle, WA USA

[4] Roswell Park Comprehens Canc Ctr, Buffalo, NY USA

[5] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA

[6] Weill Cornell Med, New York, NY USA

[7] NewYork Presbyterian Hosp, New York, NY USA

[8] Oregon Oncol Specialists, Salem, OR USA

[9] Taiho Oncol Inc, Pleasanton, CA USA

[10] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Sch Med, Nashville, TN USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

MDS; ASTX030; azacitidine; cedazuridine; oral hypomethylating agents; myelodysplastic syndromes; CMML;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MDS-773

引用

页码：S406 / S407

页数：2

共 42 条

[1] Development of Oral Azacitidine with Cedazuridine for Myelodysplastic Syndrome (MDS) and Myeloproliferative Neoplasms ( MPN) Including CMML (Chronic Myelomonocytic Leukemia) By Targeting Pharmacokinetic AUC Equivalence Vs Subcutaneous Azacitidine
Garcia-Manero, Guillermo
McCloskey, James
Scott, Bart L.
Griffiths, Elizabeth A.
Kiner-Strachan, Bonnie
Roboz, Gail J.
Meyer, Janelle
Chan, Winny
Mirakhur, Beloo
Sano, Yuri
Oganesian, Aram
Keer, Harold N.
Savona, Michael R.
BLOOD, 2023, 142
[2] Final results of a phase II study of tipifarnib in chronic myelomonocytic leukemia (CMML) and other myelodysplastic/myeloproliferative neoplasms (MDS/MPN)
Patnaik, M. M.
Sekeres, M. A.
DeZern, A.
Luger, S.
Sproat, L.
Bejar, R.
Hobbs, G.
Roboz, G. J.
Leoni, M.
Martell, B.
Padron, E.
ANNALS OF ONCOLOGY, 2021, 32 : S783 - S784
[3] Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria*
Triguero, A.
Xicoy, B.
Zamora, L.
Jimenez, M. J.
Garcia, O.
Calabuig, M.
Diaz-Beya, M.
Arzuaga, J.
Ramos, F.
Medina, A.
Bernal, T.
Talarn, C.
Coll, R.
Collado, R.
Chen, T. Hua
Borras, J.
Brunet, S.
Marchante, I
Marco, V
Lopez-Cadenas, F.
Calbacho, M.
Simiele, A.
Cortes, M.
Cedena, M. T.
Pedreno, M.
Aguilar, C.
Pedro, C.
Fernandez, M.
Stoica, C.
Ribera, J. M.
Sanz, G.
LEUKEMIA RESEARCH, 2022, 116
[4] Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure
Harel, Stephanie
Cherait, Amina
Berthon, Celine
Willekens, Christophe
Park, Sophie
Rigal, Marthe
Brechignac, Sabine
Thepot, Sylvain
Quesnel, Bruno
Gardin, Claude
Ades, Lionel
Fenaux, Pierre
Braun, Thorsten
LEUKEMIA RESEARCH, 2015, 39 (05) : 501 - 504
[5] Treatment With Decitabine (DAC) After Azacitidine (AZA) Failure In High Risk Myelodysplastic Syndrome (MDS) and Advanced Chronic Myelomonocytic Leukemia (CMML)
Braun, Thorsten
Cherait, Amina
Berthon, Celine
Willekens, Christophe
Park, Sophie
Rigal, Marthe
Brechignac, Sabine
Harel, Stephanie
Thepot, Sylvain
Quesnel, Bruno
Gardin, Claude
Ades, Lionel
Fenaux, Pierre
BLOOD, 2013, 122 (21)
[6] Efficacy of Azacitidine (AZA) in Autoimmune and Inflammatory Disorders (AID) Associated with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Fraison, Jean-Baptiste
Mekinian, Arsene
Grignano, Eric
Kahn, Jean-Emmanuel
Arlet, Jean-Benoit
Decaux, Olivier
Guillaume, Denis
Buchdahl, Anne-Laure
Omouri, Mohamed
Maigne, Gwenola
Aouba, Achille
Leon, Nathalie
Berthier, Sabine
Liozon, Eric
Park, Sophie
Gardin, Claude
Lortholary, Olivier
Rossignol, Julien
Fenaux, Pierre
Fain, Olivier
Braun, Thorsten
BLOOD, 2015, 126 (23)
[7] Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Savona, Michael R.
McCloskey, James K.
Griffiths, Elizabeth A.
Yee, Karen W. L.
Al-Kali, Aref
Zeidan, Amer M.
Deeg, H. Joachim
Patel, Prapti A.
Sabloff, Mitchell
Keating, Mary-Margaret
Kim-Hien Dao
Zhu, Nancy
Gabrail, Nashat
Fazal, Salman
Maly, Joseph
Odenike, Olatoyosi
Kantarjian, Hagop M.
DeZern, Amy E.
O'Connell, Casey L.
Roboz, Gail J.
Busque, Lambert
Wells, Richard A.
Amin, Harshad
Randhawa, Jasleen K.
Leber, Brian
Hao, Yong
Keer, Harold N.
Azab, Mohammad
Garcia-Manero, Guillermo
BLOOD, 2020, 136
[8] Results of 5-azacitidine therapy in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML)
Freyrie, A.
Reda, G.
Vincenti, D.
Ferla, V.
Orofino, N.
Sciume, M.
Guidotti, F.
Cortelezzi, A.
LEUKEMIA RESEARCH, 2013, 37 : S157 - S158
[9] A phase 2 study of azacitidine (5-AZA) with or without birinapant in subjects with higher risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML).
Donnellan, William Bruce
Diez-Campelo, Maria
Heuser, Michael
Ritchie, Ellen K.
Skolnik, Jeffrey
Font, Patricia
Komrokji, Rami S.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[10] EXTENDED CC-486 (ORAL AZACITIDINE) DOSING IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS), ACUTE MYELOID LEUKEMIA (AML), OR CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): SAFETY, TOLERABILITY, AND RESPONSE
Savona, M. R.
Kolibaba, K.
Conkling, P.
Kingsley, E. C.
Becerra, C.
Morris, J. C.
Rifkin, R. M.
Laille, E.
Kellerman, A.
Ukrainskyj, S. M.
Dong, Q.
Skikne, B. S.
LEUKEMIA RESEARCH, 2015, 39 : S29 - S30

← 1 2 3 4 5 →